Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway Corrigendum in /10.3892/ijo.2016.3714

Li,Bo; Yang,Yuehua; Jiang,Shengdan; Ni,Binbin; Chen,Ke; Jiang,Leisheng

doi:10.3892/ijo.2012.1617

Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway

Corrigendum in: /10.3892/ijo.2016.3714

Authors:
- Bo Li
- Yuehua Yang
- Shengdan Jiang
- Binbin Ni
- Ke Chen
- Leisheng Jiang
View Affiliations

Affiliations: Department of Orthopedic Surgery, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200092, P.R. China
Published online on: September 4, 2012 https://doi.org/10.3892/ijo.2012.1617
Pages: 1809-1819

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily of signaling molecules and have previously been shown to be associated with the biological behavior of osteosarcoma. However, to date the effects and molecular mechanisms of BMP-9 on osteosarcoma progression are unknown. We performed real-time PCR and western blot analysis to characterize the endogenous expression of BMP-9 in osteosarcoma cell lines. We used a recombinant adenovirus expressing BMP-9 (adBMP-9) to infect osteosarcoma cell lines with relatively low endogenous BMP-9 expression to determine the functional relevance of BMP-9 overexpression to osteosarcoma cell growth and migration in vitro and in vivo, and further investigated the expression levels of Ki-67, matrix metallopeptidase-9 (MMP-9), phosphoinositide 3-kinase p85α (PI3Kp85α) and phosphorylated AKT (p-AKT). As a result, osteosarcoma cell proliferation and migration were significantly diminished by adBMP-9, indicated by MTT and wound-healing assays, and cell apoptosis was markedly induced, indicated by Hoechst 33342/PI assay and Annexin V-FITC apoptosis detection. When BMP-9 expression was enhanced, the expression of PI3Kp85α, p-AKT, Ki-67 and MMP-9 was downregulated in osteosarcoma cells. In addition, the tumor volumes in MG-63 and HOS subcutaneous nude mouse models treated with adBMP-9 were significantly smaller compared to those of the ad-GFP group. These results suggested that the enhanced expression of BMP-9 in osteosarcoma cells by adBMP-9 exerted inhibitory effects on growth and migration of osteosarcoma cells possibly via blockade of the PI3K/AKT signaling pathway.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Kim M and Choe S: BMPs and their clinical potentials. BMB Rep. 44:619–634. 2011. View Article : Google Scholar
3.	Boon MR, van der Horst G, van der Pluijm G, et al: Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency. Cytokine Growth Factor Rev. 22:221–229. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Gobbi G, Sangiorgi L, Lenzi L, et al: Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol. 20:143–147. 2002.PubMed/NCBI
5.	Yoshikawa H, Nakase T, Myoui A and Ueda T: Bone morphogenetic proteins in bone tumors. J Orthop Sci. 9:334–340. 2004. View Article : Google Scholar
6.	Sulzbacher I, Birner P, Trieb K, Pichlbauer E and Lang S: The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol. 55:381–385. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Sotobori T, Ueda T, Myoui A, et al: Bone morphogenetic protein-2 promotes the haptotactic migration of murine osteoblastic and osteosarcoma cells by enhancing incorporation of integrin beta1 into lipid rafts. Exp Cell Res. 312:3927–3938. 2006. View Article : Google Scholar
8.	Weiss KR, Cooper GM, Jadlowiec JA, McGough RL III and Huard J: VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res. 450:111–117. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Song JJ, Celeste AJ, Kong FM, Jirtle RL, Rosen V and Thies RS: Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology. 136:4293–4297. 1995.PubMed/NCBI
10.	Ploemacher RE, Engels LJ, Mayer AE, Thies S and Neben S: Bone morphogenetic protein 9 is a potent synergistic factor for murine hemopoietic progenitor cell generation and colony formation in serum-free cultures. Leukemia. 13:428–437. 1999. View Article : Google Scholar : PubMed/NCBI
11.	Helm GA, Alden TD, Beres EJ, et al: Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg. 92:191–196. 2000.PubMed/NCBI
12.	López-Coviella I, Berse B, Krauss R, Thies RS and Blusztajn JK: Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science. 289:313–316. 2000.
13.	Chen C, Grzegorzewski KJ, Barash S, et al: An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol. 21:294–301. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Truksa J, Peng H, Lee P and Beutler E: Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA. 103:10289–10293. 2006. View Article : Google Scholar : PubMed/NCBI
15.	David L, Mallet C, Mazerbourg S, Feige JJ and Bailly S: Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 109:1953–1961. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Brown MA, Zhao Q, Baker KA, et al: Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem. 280:25111–25118. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Scharpfenecker M, van Dinther M, Liu Z, et al: BMP-9 signals via ALK1 and inhibits hFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci. 120:964–972. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Upton PD, Davies RJ, Trembath RC and Morrell NW: Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem. 284:15794–15804. 2009. View Article : Google Scholar
19.	Ye L, Kynaston H and Jiang WG: Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res. 6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Yang LJ and Jin Y: Immunohistochemical observation of bone morphogenetic protein in normal and abnormal conditions. Clin Orthop Relat Res. 257:249–256. 1990.PubMed/NCBI
22.	Laiitnen M, Jortikka L, Halttunen T, et al: Measurement of total and local bone morphogenetic protein concentration in bone tumours. Int Orthop. 21:188–193. 1997. View Article : Google Scholar : PubMed/NCBI
23.	Yoshikawa H, Shimizu K, Nakase T and Takaoka K: Periosteal sunburst speculation in osteosarcoma. A possible role for bone morphogenetic protein. Clin Orthop Relat Res. 308:213–219. 1994.PubMed/NCBI
24.	Yoshikawa H, Retting WJ, Lane JM, et al: Immunohistochemical detection of bone morphogenetic protein in bone and soft-tissue sarcomas. Cancer. 74:842–847. 1994. View Article : Google Scholar : PubMed/NCBI
25.	Yoshikawa H, Retting WJ, Takaoka K, et al: Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody. Cancer. 73:85–91. 1994. View Article : Google Scholar
26.	Bidart M, Ricard N, Levet S, et al: BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci. 69:313–324. 2012. View Article : Google Scholar : PubMed/NCBI
27.	Suzuki Y, Ohga N, Morishita Y, et al: BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci. 123:1684–1692. 2010. View Article : Google Scholar : PubMed/NCBI
28.	Castonguay R, Werner ED, Matthews RG, et al: Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem. 286:30034–30046. 2011. View Article : Google Scholar
29.	Herrera B, van Dinther M, Ten Dijke P and Inman GJ: Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 69:9254–9262. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Hotfilder M, Sondermann P, Senss A, et al: PI3K/AKT is involved in mediating survival signals that rescue Ewing tumor cells from fibroblast growth factor 2-induced cell death. Br J Cancer. 92:705–710. 2005. View Article : Google Scholar : PubMed/NCBI
31.	Tsubaki M, Yamazoe Y, Yanae M, et al: Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma. Cytokine. 54:100–107. 2011.PubMed/NCBI
32.	Jin S, Pang RP, Shen JN, et al: Grifolin induces apoptosis via inhibition of PI3K/AKT signaling pathway in human osteosarcoma cells. Apoptosis. 12:1317–1326. 2007. View Article : Google Scholar : PubMed/NCBI
33.	Liu B, Shi ZL, Feng J and Tao HM: Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int. 32:494–501. 2008. View Article : Google Scholar
34.	Wu Z, Min L, Chen D, et al: Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One. 6:e146482011. View Article : Google Scholar : PubMed/NCBI
35.	Hernández-Rodríguez NA, Correa E, Sotelo R, et al: Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma. Cancer Detect Prev. 25:210–215. 2001.PubMed/NCBI
36.	Loukopoulos P, O’Brien T, Ghoddusi M, Mungall BA and Robinson WF: Characterization of three novel canine osteosarcoma cell lines producing high levels of matrix metal-loproteinases. Res Vet Sci. 77:131–141. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol. 20:983–1002. 2006. View Article : Google Scholar : PubMed/NCBI
38.	Fu Y, Zhang Q, Kang C, et al: Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. Int J Oncol. 35:583–591. 2009.